Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1084
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media? ; day:2 ; month:12 ; year:2020 ; pages:1-11
European radiology ; (2.12.2020), 1-11
- Creator
-
Huebner, Nicolai Alexander
Korn, Stephan
Resch, Irene
Grubmüller, Bernhard
Gross, Tobias
Gale, Robert
Kramer, Gero
Poetsch, Nina
Clauser, Paola
Haitel, Andrea
Fajkovic, Harun
Shariat, Shahrokh F.
Baltzer, Pascal Andreas Thomas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00330-020-07494-1
- URN
-
urn:nbn:de:101:1-2021011118054498729424
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Huebner, Nicolai Alexander
- Korn, Stephan
- Resch, Irene
- Grubmüller, Bernhard
- Gross, Tobias
- Gale, Robert
- Kramer, Gero
- Poetsch, Nina
- Clauser, Paola
- Haitel, Andrea
- Fajkovic, Harun
- Shariat, Shahrokh F.
- Baltzer, Pascal Andreas Thomas
- SpringerLink (Online service)
Other Objects (12)
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
MRI as a screening tool for prostate cancer: current evidence and future challenges